Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06536491

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

Led by Eclipse Life Sciences, Inc. · Updated on 2025-01-22

75

Participants Needed

1

Research Sites

71 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).

CONDITIONS

Official Title

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males or females who are at least 18 years of age at the time of informed consent
  • Willing and able to provide signed informed consent and comply with all study visits and examinations
  • Diagnosis of diabetes mellitus (Type 1 or Type 2) with history of diabetic macular edema (DME) of any duration
  • Currently have hemoglobin A1c values 4.0 or less under diabetes care, unless the provider allows a variance
  • Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA score of 70 letters or less (20/40 or worse) and at least 20 letters (20/400) in at least one eye
Not Eligible

You will not qualify if you...

  • Previous or current diagnosis of any form of glaucoma or ocular hypertension requiring medical or surgical intervention
  • History of steroid-induced intraocular pressure (IOP) elevation greater than 25 mm Hg
  • Presence of active proliferative diabetic retinopathy, including active neovascularization of the disc, elsewhere, iris, angle, or vitreous hemorrhage associated with neovascularization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Retina Associates of Florida, LLC

Tampa, Florida, United States, 33609

Actively Recruiting

Loading map...

Research Team

F

Freddie Batalla, MBA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here